ANTIBIOBONTA - Assessment of the interest of a peri-operative antibiotic strategy applied to patients with asymptomatic bacteriuria undergoing intra-vesical botulinum toxin A injections

Prior treatment

• Contra-Indication to botulinum toxin a, and excipients included in study drugs
• Ongoing cyclic antibiotic therapy
• Ongoing corticosteroid therapy
• Modification of immunosuppressive or immunomodulatory therapy in the 3 months before inclusion
• Antibiotic therapy in the month before inclusion
• Surgical procedure in the 3 months before and the 6 weeks following inclusion

Other illness

• Patients incapable to follow the trial, e.g. because of language problems, psychiatric disorders, dementia and so on.
• Associated neurologic disease
• Pregnancy or breast feeding
  • Having already participated to the study
  • Augmentation cystoplasty
  • Bladder compliance disorders (<20 mL/cmH2O)
  • Morphologic urinary tract abnormalities considered as a risk factor for recurrent symptomatic UTI

Other

• Absence of use of any recognized contraceptive method (e.g. hormonal, barrier, IUD, sterilization) or of consistent sexual abstinence
• Individuals especially in need of protection
• No informed consent
• Immunocompromised patients
• Patient without easy access to internet within 6 weeks of the injection
• Symptomatic UTI at the time of inclusion

• Female and male over 18 years-old
• Multiple Sclerosis or Spinal Cord Injury (traumatic or non-traumatic)
• Clean Intermittent Self-Catheterization as the exclusive bladder management
• Refractory Detrusor Overactivity leading to urinary incontinence (failure, intolerance or contra-indication to anti-muscarinic therapy)
• Treated with intra-vesical BoNTA injections having proved efficacy
• Asymptomatic Bacteriuria (bacteriuria threshold ≥ 10² CFU/mL) on pre-operative urine analysis (performed 5 days (+/- 2 days) before intra-vesical BoNTA injections)
• With a personal and functional e-mail address, a quasi-permanent Internet connection and a mobile phone.